Annegien Broeks

Summary

Affiliation: The Netherlands Cancer Institute
Country: The Netherlands

Publications

  1. pmc Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients
    Marjanka K Schmidt
    Departments of Epidemiology, Experimental Therapy and Pathology, Netherlands Cancer Institute, The Netherlands
    Breast Cancer Res 11:R89. 2009
  2. ncbi request reprint IVS10-6T>G, an ancient ATM germline mutation linked with breast cancer
    Annegien Broeks
    Department of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Hum Mutat 21:521-8. 2003
  3. pmc Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium
    Annegien Broeks
    Department of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Hum Mol Genet 20:3289-303. 2011
  4. pmc Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study
    Annegien Broeks
    Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 9:R26. 2007
  5. pmc The spectrum of ATM missense variants and their contribution to contralateral breast cancer
    Annegien Broeks
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res Treat 107:243-8. 2008
  6. ncbi request reprint Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers
    Annegien Broeks
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam
    Breast Cancer Res Treat 83:91-3. 2004
  7. doi request reprint Radiation-associated breast tumors display a distinct gene expression profile
    Annegien Broeks
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 76:540-7. 2010
  8. doi request reprint Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes
    Marie L De Bruin
    Department of Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    J Clin Oncol 27:4239-46. 2009
  9. doi request reprint Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups
    Alexandra J van den Broek
    Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res Treat 130:599-608. 2011
  10. ncbi request reprint Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation
    Marjanka K Schmidt
    Department of Epidemiology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    J Clin Oncol 25:64-9. 2007

Detail Information

Publications15

  1. pmc Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients
    Marjanka K Schmidt
    Departments of Epidemiology, Experimental Therapy and Pathology, Netherlands Cancer Institute, The Netherlands
    Breast Cancer Res 11:R89. 2009
    ..We investigated the effects of the germ-line single nucleotide polymorphisms TP53 R72P (215G>C) and MDM2 SNP309 (-410T>G), and p53 protein expression in breast tumors on survival...
  2. ncbi request reprint IVS10-6T>G, an ancient ATM germline mutation linked with breast cancer
    Annegien Broeks
    Department of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Hum Mutat 21:521-8. 2003
    ..Our results predict that this mutation could be widely distributed across Europe and, probably, the Middle East and Western Asia...
  3. pmc Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium
    Annegien Broeks
    Department of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Hum Mol Genet 20:3289-303. 2011
    ..This may eventually result in further improvements in prevention, early detection and treatment...
  4. pmc Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study
    Annegien Broeks
    Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 9:R26. 2007
    ..Radiation exposure at a young age is one of the strongest risk factors for breast cancer. Germline mutations in genes involved in the DNA-damage repair pathway (DDRP) may render women more susceptible to radiation-induced breast cancer...
  5. pmc The spectrum of ATM missense variants and their contribution to contralateral breast cancer
    Annegien Broeks
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res Treat 107:243-8. 2008
    ..029). Our results indicate that the presence of ATM variants does not have a major impact on the overall risk of CBC. However, the combination of RT and (certain) ATM missense variants seems to accelerate tumour development...
  6. ncbi request reprint Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers
    Annegien Broeks
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam
    Breast Cancer Res Treat 83:91-3. 2004
    ..These results warrant prolonged medical surveillance and may indicate a clinically important interaction between CHEK2 heterozygosity and radiation in the development of contralateral breast cancer...
  7. doi request reprint Radiation-associated breast tumors display a distinct gene expression profile
    Annegien Broeks
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 76:540-7. 2010
    ..Approximately 90% of the breast cancers in these patients can be attributed to their radiation treatment, rendering such series extremely useful to determine whether a common radiation-associated cause underlies the carcinogenic process...
  8. doi request reprint Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes
    Marie L De Bruin
    Department of Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    J Clin Oncol 27:4239-46. 2009
    ..We assessed the long-term risk of breast cancer (BC) after treatment for Hodgkin's lymphoma (HL). We focused on the volume of breast tissue exposed to radiation and the influence of gonadotoxic chemotherapy (CT)...
  9. doi request reprint Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups
    Alexandra J van den Broek
    Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res Treat 130:599-608. 2011
    ..TT-genotype HR 2.99, P = 0.06). These results indicate that common polymorphisms in specific pathways may add to the worse prognosis of patients with tumors in which these pathways are affected by somatic alterations...
  10. ncbi request reprint Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation
    Marjanka K Schmidt
    Department of Epidemiology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    J Clin Oncol 25:64-9. 2007
    ....
  11. ncbi request reprint Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium
    Marjanka K Schmidt
    Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cancer Res 67:9584-90. 2007
    ..This suggests that any effect of these two variants would be very small and possibly confined to subgroups that were not assessed in our present study...
  12. pmc The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype
    Marielle W G Ruijs
    Family Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Hered Cancer Clin Pract 7:4. 2009
    ..The prevalence of CHEK2*1100delC differs between populations and has been found to be relatively high in the Netherlands. The question remains nevertheless whether CHEK2 germline mutations contribute to the Li-Fraumeni phenotype...
  13. ncbi request reprint Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease
    Flora E van Leeuwen
    Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Natl Cancer Inst 95:971-80. 2003
    ..Female survivors of Hodgkin's disease (HD) have a strongly elevated risk of breast cancer, but factors responsible for the increased risk are not well known...
  14. ncbi request reprint Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles?
    Csilla I Szabo
    International Agency for Research on Cancer, Lyon, France
    Cancer Res 64:840-3. 2004
    ..008. We conclude that the ATM IVS10-6T-->G mutation does not confer a significantly elevated breast cancer risk and that ATM 7271T-->G is a rare event in familial breast cancer...
  15. ncbi request reprint A common coding variant in CASP8 is associated with breast cancer risk
    Angela Cox
    Sheffield University Medical School, Sheffield S10 2RX, UK
    Nat Genet 39:352-8. 2007
    ..02-1.13) and 1.16 (95% c.i.: 1.08-1.25), respectively; P(trend) = 2.8 x 10(-5)). These results demonstrate that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies...